Two major Alzheimer’s research updates surfaced: one review argued that CRISPR-based editing of APOE4 alleles could reduce genetic risk, and a Nature Communications study reported blood biomarkers tracking Alzheimer’s across cognitive stages in community cohorts. The CRISPR piece framed APOE4 modification as a potential route to lower disease susceptibility, while the biomarker paper validated accessible plasma signatures linked to cognitive decline. Together the reports move genetics and fluid biomarkers closer to clinical translation. CRISPR approaches aim to convert high‑risk APOE4 alleles into lower‑risk isoforms, a concept still preclinical, while validated blood biomarkers could accelerate trial enrollment and longitudinal monitoring. Both developments will interest companies building gene-editing platforms, assay developers, and trial sponsors seeking stratified patient populations.